Diarrhea News and Research

Latest Diarrhea News and Research

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors.

1 Feb 2012

Vertex receives FDA approval for Kalydeco to treat rare form of CF

The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.

1 Feb 2012

Roche’s skin cancer drug Erivedge gets FDA nod

The Food and Drugs Administration (FDA) this Monday approved a pill that treats the most common type of skin cancer, basal cell carcinoma.

31 Jan 2012

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.

31 Jan 2012

FDA approves Genentech's Erivedge for treatment of BCC

Genentech, a member of the Roche Group, today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.

31 Jan 2012

Genentech receives FDA approval for Erivedge to treat basal cell carcinoma

Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body.

31 Jan 2012

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

AMAG Pharmaceuticals, Inc. today announced the completion of patient enrollment in the second of the company's two phase III studies that comprise its global registrational program for Feraheme (ferumoxytol) in patients with iron-deficiency anemia (IDA) who are not candidates for oral iron, regardless of the underlying cause.

30 Jan 2012

Inlyta receives FDA approval for treatment of advanced kidney cancer

The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.

30 Jan 2012

Access to, use of sanitation systems cuts odds of worm infection in half, study review shows

When sanitation systems are available and used, the odds of contracting one of a group of diseases, known as soil-transmitted helminths (STH), is cut in half, according to a systemic review and meta-analysis published this week in PLoS Medicine, Examiner.com reports (Herriman, 1/25).

30 Jan 2012

Creighton researcher to study role of adult stem cells in repairing damaged coronary arteries

A Creighton University School of Medicine researcher has received a $3.3 million, five-year grant from the National Institutes of Health to study what role adult stem cells might play in repairing damaged coronary arteries, a complication that often occurs in patients after they undergo angioplasty and stenting.

24 Jan 2012

Pakistan's polio eradication program facing challenges after increase in cases last year

IRIN examines several factors that could be contributing to an increase in polio cases in Pakistan, "despite the launch of a National Emergency Action Plan for Polio Eradication" at the beginning of 2011. In 2010, Pakistan recorded 144 cases of polio and 192 cases in 2011, the news service reports.

24 Jan 2012

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.

24 Jan 2012

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

21 Jan 2012

Positive preliminary data from Exelixis' cabozantinib phase 2 trial on HCC

Exelixis, Inc. today reported positive preliminary data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.

20 Jan 2012

Experimental drug helps patients with advanced colon cancer

According to results from a new clinical trial, an experimental cancer drug regorafenib appears to extend survival slightly in patients with metastatic colorectal cancer. Regorafenib is a so-called multikinase inhibitor, which targets several of the ways cancer develops and grows, researchers said.

19 Jan 2012

Study demonstrates possibility of curing hepatitis C without use of interferon

Bristol-Myers Squibb Company today announced the full results, published in the New England Journal of Medicine, from a Phase II clinical trial in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin ('null responders').

19 Jan 2012

New combo drug helps suppress hepatitis C genotype 1 infection

A new combination of investigational drugs successfully suppressed hepatitis C genotype 1 infection in a high percent of patients who had not responded to previous treatment in a study led by a University of Michigan hepatologist.

19 Jan 2012

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Viread in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients ages 2-12.

19 Jan 2012

ViroPharma's NDS for Cinryze receives Health Canada's Priority Review status

ViroPharma Incorporated today announced that Health Canada has granted the company Priority Review status for its New Drug Submission (NDS) for Cinryze (C1 inhibitor [human]).

13 Jan 2012

Investing in Frontline Health Workers effective in saving lives of mothers, children

In the Huffington Post's "Impact" blog, Carolyn Miles, president and CEO of Save the Children, writes about the Frontline Health Workers Coalition's call on the U.S. government to train 250,000 new frontline health workers in developing countries, stating, "At a time when every dollar counts more than ever, the new Frontline Health Workers Coalition believes this focus is the most cost-effective way to save mothers' and children's lives around the world, address global health threats, and help advance strategic U.S. interests in a secure and prosperous world."

12 Jan 2012

Diarrhea News and Research

Latest Diarrhea News and Research

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

Vertex receives FDA approval for Kalydeco to treat rare form of CF

Roche’s skin cancer drug Erivedge gets FDA nod

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

FDA approves Genentech's Erivedge for treatment of BCC

Genentech receives FDA approval for Erivedge to treat basal cell carcinoma

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

Inlyta receives FDA approval for treatment of advanced kidney cancer

Access to, use of sanitation systems cuts odds of worm infection in half, study review shows

Creighton researcher to study role of adult stem cells in repairing damaged coronary arteries

Pakistan's polio eradication program facing challenges after increase in cases last year

Takeda receives FDA approval for VELCADE sNDA to treat MM

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

Positive preliminary data from Exelixis' cabozantinib phase 2 trial on HCC

Experimental drug helps patients with advanced colon cancer

Study demonstrates possibility of curing hepatitis C without use of interferon

New combo drug helps suppress hepatitis C genotype 1 infection

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

ViroPharma's NDS for Cinryze receives Health Canada's Priority Review status

Investing in Frontline Health Workers effective in saving lives of mothers, children

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in